Video

Real-World Community Practice Experience With Luspatercept Following Erythropoiesis-Stimulating Agent Failure in Patients With Lower-Risk Myelodysplastic Syndromes

Rapid Reactions

Guillermo Garcia-Manero, MD, from MD Anderson Cancer Center, characterizes the clinical outcome improvements observed with luspatercept for lower-risk myelodysplastic syndromes in clinical practice.
Supported through funding from
Bristol Myers Squibb

Evaluating Oral Azacitidine for the Treatment of Low- or Intermediate-Risk Myelodysplastic Syndromes

Rapid Reactions

Please join Guillermo Garcia-Manero, MD, from MD Anderson Cancer Center, as he describes the study design of a new phase 2/3 study evaluating oral azacitidine for the treatment of myelodysplastic syndromes.
Supported through funding from
Bristol Myers Squibb

$IMerge Clinical Data in Patients With Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to Erythropoiesis-Stimulating Agents$

IMerge Clinical Data in Patients With Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to Erythropoiesis-Stimulating Agents

Rapid Reactions

Guillermo Garcia-Manero, MD, from MD Anderson Cancer Center, explores imetelstat trial results of patients with transfusion-dependent lower-risk myelodysplastic syndromes who experience failure to or are ineligible for treatment with erythropoiesis-stimulating agents.
Supported through funding from
Bristol Myers Squibb

COMMANDS Study Results May Shift the Treatment of Patients With Lower-Risk Myelodysplastic Syndromes

Rapid Reactions

Please join Guillermo Garcia-Manero, MD, from MD Anderson Cancer Center, as he discusses how the clinical benefits of luspatercept could lead to a new standard of care for patients with transfusion-dependent lower-risk myelodysplastic syndromes.
Supported through funding from
Bristol Myers Squibb